Skip to main content

On the use of surrogate end points in randomized trials

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

In a recent paper Day and Duffy proposed a strategy for designing a randomized trial of different breast cancer screening schedules. Their strategy was based on the use of predictors of mortality determined by patients' factors at diagnosis as surrogates for true mortality. On the basis of the Prentice criterion for validity of a surrogate end point, and data from earlier studies of breast cancer case survival, they showed that, not only would the trial require a much shorter follow-up, but also that the information (i.e. inverse variance) for evaluating a treatment effect on mortality would be greater by a factor of nearly 3 if the predictors of mortality were used, compared with a trial in which mortality was actually observed. Although these results are technically correct, we believe that the conceptual strategy on which they are based is flawed, and that the fundamental problem is the Prentice criterion itself. In this paper the technical issues are discussed in detail, and an alternative structure for evaluating the validity of surrogate end points is proposed.

Keywords: Randomized trials; Surrogate end points

Document Type: Original Article

DOI: https://doi.org/10.1111/1467-985X.00153

Affiliations: Memorial Sloan-Kettering Cancer Center, New York, USA

Publication date: 2000-02-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more